The broad, long-range objective of the Translational Incubator Core (Core C) is to enhance and accelerate the translational aspects of the Center's goals to develop new classes of host-targeting antiviral therapeutics that are capable of treating multiple NIAID Emerging and Re-emerging Priority Pathogen viruses, when used alone or in combination with other available agents. The Translational Incubator Core will be responsible for providing strategic scientific, regulatory, preclinical and clinical guidance to all U19 research projects. The Core will assist projects in establishing Target Product Profiles and Development Plans for advancing their therapeutics towards the clinic. The Core will provide guidance in areas such as appropriate use of in vitro assays and in vivo models to demonstrate efficacy, pharmacokinetics, ADME (absorption, distribution, metabolism, and excretion), and preclinical safety. When appropriate, the Translational Incubator Core will provide advice regarding commercialization options when this is required to further advance the project. In addition, each year the Core will select and provide guidance to pilot projects to develop therapeutics or supportive technologies that address emerging or re-emerging infectious diseases and are both consonant with the translational research theme of the Center and capable of enhancing existing projects. The Translational Incubator Core will seek to achieve these objectives via the following specific aims: 1) To provide regulatory science expertise and support to all participating research projects. 2) To provide strategic advice, expertise and practical support on the translational aspects of the Center's projects, thereby accelerating progress in accomplishment of preclinical development activities. 3) To identify research projects and technologies within the greater Stanford community that could directly enhance the Center's projects and translational efforts to develop new classes of host-targeting antiviral therapies
In summary, we seek to develop new classes of host-targeting antiviral therapeutics that are capable of treating multiple NIAID Emerging and Re-emerging Priority Pathogen viruses, when used alone or in combination with other available agents.
Feinberg, Evan N; Sur, Debnil; Wu, Zhenqin et al. (2018) PotentialNet for Molecular Property Prediction. ACS Cent Sci 4:1520-1530 |
Robinson, Makeda; Schor, Stanford; Barouch-Bentov, Rina et al. (2018) Viral journeys on the intracellular highways. Cell Mol Life Sci 75:3693-3714 |
Schor, Stanford; Einav, Shirit (2018) Combating Intracellular Pathogens with Repurposed Host-Targeted Drugs. ACS Infect Dis 4:88-92 |
Sweeney, Timothy E; Wynn, James L; Cernada, MarĂa et al. (2018) Validation of the Sepsis MetaScore for Diagnosis of Neonatal Sepsis. J Pediatric Infect Dis Soc 7:129-135 |
Wu, Zhenqin; Ramsundar, Bharath; Feinberg, Evan N et al. (2018) MoleculeNet: a benchmark for molecular machine learning. Chem Sci 9:513-530 |
Dudek, Amanda M; Pillay, Sirika; Puschnik, Andreas S et al. (2018) An Alternate Route for Adeno-associated Virus (AAV) Entry Independent of AAV Receptor. J Virol 92: |
Gee, Marvin H; Han, Arnold; Lofgren, Shane M et al. (2018) Antigen Identification for Orphan T Cell Receptors Expressed on Tumor-Infiltrating Lymphocytes. Cell 172:549-563.e16 |
Barouch-Bentov, Rina; Einav, Shirit (2018) Turning Up Your Nose for a Flaviviral Encephalitis Cure. Cell Host Microbe 23:427-429 |
Rinis, Natalia; Golden, Jennifer E; Marceau, Caleb D et al. (2018) Editing N-Glycan Site Occupancy with Small-Molecule Oligosaccharyltransferase Inhibitors. Cell Chem Biol 25:1231-1241.e4 |
Constant, David A; Mateo, Roberto; Nagamine, Claude M et al. (2018) Targeting intramolecular proteinase NS2B/3 cleavages for trans-dominant inhibition of dengue virus. Proc Natl Acad Sci U S A 115:10136-10141 |
Showing the most recent 10 out of 73 publications